Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 12Pancreatic Neoplasms 6Neoplasms 6Prostatic Neoplasms 5Ovarian Neoplasms 5Leukemia, Myeloid, Acute 5Head and Neck Neoplasms 5Urinary Bladder Neoplasms 4Multiple Myeloma 4Lung Neoplasms 4Leukemia 4Colorectal Neoplasms 4Recurrence 3Neoplasms, Plasma Cell 3Hematologic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Rectal Neoplasms 2Radiodermatitis 2Neoplasms by Site 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Melanoma 2Glioma 2Glioblastoma 2Gastrointestinal Neoplasms 2Communication 2Carcinoma, Transitional Cell 2Anatomic Stage I Breast Cancer AJCC v8 2Uterine Cervical Neoplasms 1Urologic Neoplasms 1

Interventions

Gemcitabine 4130-nm albumin-bound paclitaxel 4pembrolizumab 3napabucasin 3Paclitaxel 3Irinotecan 3selpercatinib 2pralsetinib 2patritumab 2Standard of Care 2Pemetrexed 2Nivolumab 2Fluorouracil 2Cyclophosphamide 2Cisplatin 2Carboplatin 2Ascorbic Acid 2Albumin-Bound Paclitaxel 2valrubicin 1sotorasib 1ribociclib 1relatlimab 1pamiparib 1osimertinib 1ipatasertib 1durvalumab 1dostarlimab 1cobimetinib 1atezolizumab 1alectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Neoplasms by Site × Standard of Care × Clear all
NCT01310803 2017-10-05

Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder

Endo Pharmaceuticals

Phase 3 Terminated
1 enrolled 5 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

NCT01353222 2017-05-25

DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma

Dendreon

Phase 2 Terminated
142 enrolled 13 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡